Suppr超能文献

成人弥漫性胶质瘤治疗的临床实践指南。

Clinical practice guidelines for the management of adult diffuse gliomas.

机构信息

Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China; Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, 100070, China; China National Clinical Research Center for Neurological Diseases, Beijing, 100070, China; Research Units of Accurate Diagnosis and Treatment of Brain Tumors and Translational Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China.

Department of Neurosurgery, Samsung Medical Center, South Korea.

出版信息

Cancer Lett. 2021 Feb 28;499:60-72. doi: 10.1016/j.canlet.2020.10.050. Epub 2020 Nov 6.

Abstract

To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee of Chinese Glioma Cooperative Group (CGCG), Society for Neuro-Oncology of China (SNO-China) and Chinese Brain Cancer Association (CBCA) updated the clinical practice guideline. It provides recommendations for diagnostic and management decisions, and for limiting unnecessary treatments and cost. The recommendations focus on molecular and pathological diagnostics, and the main treatment modalities of surgery, radiotherapy, and chemotherapy. In this guideline, we also integrated the results of some clinical trials of immune therapies and target therapies, which we think are ongoing future directions. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China and other countries.

摘要

为了遵循世界卫生组织(WHO)第四版分类的修订以及弥漫性神经胶质瘤管理方面的最新进展,中国神经肿瘤协作组(CGCG)、中国神经肿瘤学会(SNO-China)和中国脑肿瘤协会(CBCA)的联合指南委员会更新了临床实践指南。本指南提供了诊断和管理决策以及限制不必要治疗和费用的建议。这些建议侧重于分子和病理诊断以及手术、放疗和化疗的主要治疗方式。在本指南中,我们还整合了一些免疫治疗和靶向治疗临床试验的结果,我们认为这些是未来的发展方向。本指南应作为所有参与管理成人弥漫性神经胶质瘤患者的专业人员的应用指南,也是中国和其他国家参与癌症治疗费用管理的保险公司和其他机构的知识来源。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验